

INDEX

- abortion *see* induced abortion; miscarriage
- abstinence, sexual *see* back-up contraception/abstinence from sex
- access to contraception 251–2
- achondroplasia 503
- acitretin 323–5, 477
- acne
 - Dianette® therapy 9, 49, 50–1, 53–4
 - in cerebral palsy 52
 - combined pill after 55–6
 - postpartum, and prior acoustic neuroma 368–9
 - isotretinoin therapy 320–3
 - in polycystic ovary syndrome 542, 543
- acoustic neuroma, past history 368–9
- acrocyanosis 503–4
- ACTH-secreting pituitary tumours 366
- Actinomyces israelii 271, 272–3
- actinomyces-like organisms
 - detected by cervical smears 271, 272–3
 - detected prior to IUD insertion 148
 - postmenopausal women with IUDs 178–9
- actinomycosis, pelvic 271, 272–3
- acute macular neuroretinopathy (AMNR) 369
- Addison's disease 504–5, 528
- adhesions
 - intraperitoneal IUD-related 173, 178
 - intrauterine (Asherman syndrome) 506–7
- adolescents
 - under 16 years, consent issues 258, 260, 385, 508–9
- cerebrovascular disease 384–5
- dysmenorrhoea 35–6
- legal and ethical issues 258–60, 260, 262–4
- progestogen-only emergency contraception 224, 230–1
- progestogen-only injectables 84–6, 90
- smokers with small ventricular septal defect 401–2
- walk-in style services 247–9
- see also* young women
- adrenaline *see* epinephrine
- adrenal insufficiency 504–5, 528
- adrenocorticotrophic hormone-secreting pituitary tumours 366
- African Caribbean women, perimenopausal 87–8
- age restrictions
 - progestogen-only injectables 90–1
 - progestogen-releasing implants 119
 - see also* older women; young women
- AIDS *see* HIV infection
- allergic reactions
 - nonoxynol-9 207–8
 - progestogen-only injectables 100–5
 - see also* anaphylactic reactions
- alopecia 21–2
- androgenic 21, 22
- areata 21
- alpha-1 antitrypsin deficiency 450–1
- 5-alpha reductase 21
- Alport syndrome 473–4
- altitudes, extreme 18
- amenorrhoea
 - in anorexia nervosa 505–6

- DMPA-induced 90, 91–2, 96
- induction, valvular heart disease and
 - previous stroke 406
- lactational 60
- LNG-IUS-induced 182–3, 192
- perimenopausal 61, 86
- post-pill secondary 20
- weight-related 20
- aminoglutethimide 514
- anaesthesia, Chinese steel ring IUD
 - removal 217–18
- anaphylactic reactions
 - LNG-IUS 102, 187–8, 190
 - progestogen-only injectables 100–5
 - resuscitation guidance 100–2, 103, 250
- androgen therapy 129
- angina 429–30
- anorexia nervosa 505–6
- anovaginal fistula 506
- anti-arrhythmic agents 413–14
- antibiotics
 - in cystic fibrosis 515
 - infections prior to IUD insertion 148–9
 - liver enzyme-inducing, interactions 309–10
 - non-liver enzyme-inducing, interactions 311–5
 - oral regimens for PID 274
 - pelvic actinomycosis 272–3
 - pelvic inflammatory disease in IUD users 166
 - during pill-free interval of combined pill 45–6
 - progestogen-only pill and 74
 - prophylactic *see* antimicrobial prophylaxis
 - timing of induced abortion and 235
- anticoagulant therapy 433–5
 - combined oral contraception 442–3
 - endocarditis prophylaxis and 189–90
 - intrauterine contraception 391–2, 433–4, 434–5
 - progestogen-only implants 411–12, 438–9
- see also* warfarin
- anticonvulsant drugs 343–9, 427
 - in bipolar affective disorder 511
 - etonogestrel implants and 300, 349
 - liver-enzyme inducers 343–4, 349, 391
 - non-liver-enzyme inducers 345–8, 349
 - progestogen-only emergency contraception and 307, 343–4
- anti-epileptic drugs *see* anticonvulsant drugs
- antifibrinolytic agents 193
- anti-fungal drugs 315
- antihistamines
 - in anaphylaxis 103, 250
 - interactions 335–6
- antimicrobial prophylaxis
 - etonogestrel implant insertion/removal 403–4
 - female sterilisation 402
 - induced abortion 233–4
 - IUD insertion/removal 145–7, 153, 186–7
 - cardiomyopathy 189–90
 - coronary artery stents 430–1
 - past history of endocarditis 407–8
 - post-splenectomy 157–8, 556–7
 - valvular heart disease 157, 407–8
- antiphospholipid syndrome
 - combined oral contraception 26, 439, 479, 548, 549
 - LNG-IUS 183–4
 - progestogen-only contraception 440
- anti-retroviral drugs 300, 493–6, 499–501
- antisepsis, vaginal 152, 153
- antithrombin III deficiency 442–3
- antituberculous drugs 561
- aortic stenosis 396–8
- aortic valve, bicuspid 400–1
- appointments-based clinics 247–9
- Arcoxia® 552
- arrhythmias 413–14
- arterial thrombosis
 - lupus anticoagulants and 26

Cambridge University Press

978-1-904-75233-2 - Family Planning Masterclass: Evidence-Based Answers to 1000 Questions

Gillian Penney, Susan Brechin and Anna Glasier

Index

[More information](#)**570 FAMILY PLANNING MASTERCLASS:** Evidence-based Answers to 1000 Questions

- see also* myocardial infarction; stroke
- Arthrotec® 335
- ascorbic acid 334
- Asherman syndrome 506–7
- Asperger syndrome 507–9
- aspirin 291
- atazanavir 493–5
- atenolol 467–8
- atrial fibrillation 412, 413–14
- atrial septal defects 400–1, 405–6
- atropine 188, 250
- attention deficit disorder, and history of stroke 387–3
- aura, migraine 350
- azathioprine 466
- azithromycin 314
- back-up contraception/abstinence from sex
- after induced abortion 237, 239
 - antibiotic users 45–6, 314
 - in epilepsy 344, 345
 - late DMPA injections 106–7
 - late norethisterone acetate injections 116
 - liver enzyme-inducing drugs 300, 301, 303, 305
 - missed combined pills 41, 42, 43
 - missed progestogen-only pills 76–7, 78–9
 - prior to stopping progestogen-only pill 75
 - progestogen-only implant insertion 124–5
 - progestogen-only implant removal 126
 - starting combined pills 11, 14
 - starting progestogen-only injectables 83, 84
 - switching combined pills 12–13
 - time-expired combined pills 44
- bacteria, incidental detection at cervical cytology 271–3
- bacterial vaginosis 271
- IUD or LNG-IUS use 148, 185–6
- prophylaxis, induced abortion 234
 - treatment before induced abortion 235
 - treatment prior to IUD or LNG-IUS insertion 188–9
- barbiturates 339
- barotrauma 19
- barrier methods 205–8
- back-up *see* back-up contraception/abstinence from sex
 - in liver disease 454–5
 - travellers to high altitudes 18
- Behcet's disease 509–10
- benign intracranial hypertension 359–63
- plus multiple other pathologies 425–7
- Betadine®, vaginal preparations 152, 153
- bicornuate uterus, LNG-IUS use 184
- bicuspid aortic valve 400–1
- bipolar affective disorder 510–12
- bleeding
- delaying *see* menstruation, delaying post-abortion, contraceptive methods and 237–8, 240–1
- bleeding disorders (dyscrasias) 527–8, 530–2, 563–5
- bleeding patterns, abnormal
- combined oral contraception 31–3
 - copper IUDs 170, 171
 - LNG-IUS 182–5, 192
 - in migraine 357
 - monthly injectables 216–17
 - progestogen-only implants 132–4
 - progestogen-only injectables 96–8, 115, 521
 - progestogen-only pill 69–70
 - see also* breakthrough bleeding; intermenstrual bleeding; menorrhagia
- blood pressure 3–4, 19, 57–8
- see also* hypertension
- body mass index (BMI) 537
- combined oral contraception and 4–5

- drug interactions and 303–4
 - high *see* obesity
 - progestogen-only implants and 121–2
 - progestogen-only injectables and 82, 97–8, 99
- body weight *see* weight, body
- bone mineral density
 - desogestrel-only pill and 64–5
 - in HIV infection 497–8
 - in inflammatory bowel disease 512–14
 - progestogen-only implants and 130–1, 198
 - progestogen-only injectables and 84–6, 87–8, 90–6, 114–15
 - see also* osteoporosis
- borage (starflower) oil 331
- bosentan 304–6
- brain haemorrhage 383–5
- BRCA1 and BRCA2 gene mutations 489, 490, 491
- breakthrough bleeding
 - combined pill 8, 31–3
 - drug interactions causing 335–6
 - progestogen-only pill 71
- breast cancer 484–92
 - combined oral contraception-related risk 16, 489–90
 - estrogen receptor positive 486
 - family history 65–6, 108–9, 489–92
 - LNG-IUS as progestogen component of HRT and 282–3
 - personal history 283–5, 484–9
 - progestogen-only contraception-related risk 65–7, 108–9, 490–2
 - risk factors 67, 484
 - tamoxifen therapy 283–5, 484–8
- breastfeeding
 - combined oral contraception 6, 368
 - IUD insertion 142, 155–6
 - progestogen-only emergency contraception 223
 - progestogen-only injectables 83–4
 - progestogen-only pill 59–60
- breast lumps, in LNG-IUS users 196–7
- breast tenderness, premenstrual 287–9
- bromocriptine 334
- broom-like device, cervical smear collection 268–9
- caesarean section, IUD insertion after 155–6
- Calista® saliva ovulation test 214–15
- candidiasis, vulvovaginal 28–9, 148, 272
- cardiac arrhythmias 413–14
- cardiac laser surgery 415
- cardiac transplant recipients 415–16
- cardiomyopathy 410–12
 - dilated 410–12
 - familial 53–4
 - LNG-IUS insertion 189–90
 - peripartum 411
 - warfarin therapy 411–12
- cardiovascular disease 395–446
 - DMPA users 109–10, 386–7
 - Ehlers-Danlos syndrome and 519–20
 - family history 417–18, 425–6
 - older combined pill users 277, 278
 - renal disease and 317–18, 317–18
 - see also* cerebrovascular disorders; heart disease; stroke
- cardiovascular risk factors 419–23
 - contribution of family history 417–18
 - multiple 53, 109, 427–8
- Carpenter syndrome 405–6
- catamenial epilepsy 343
- centchroman 219–20
- Cerazette® *see* desogestrel-only pill
- cerebral infarction 386–7
 - post-meningitic 390
 - see also* stroke
- cerebral palsy 52, 370–1
- cerebral venous sinus thrombosis 390–2
- cerebral venous thrombosis 378
- cerebrospinal fluid shunts
 - benign intracranial hypertension 362–3, 425–7
 - in neurofibromatosis 374–5
- cerebrovascular accident *see* stroke

Cambridge University Press

978-1-904-75233-2 - Family Planning Masterclass: Evidence-Based Answers to 1000 Questions

Gillian Penney, Susan Brechin and Anna Glasier

Index

[More information](#)**572 FAMILY PLANNING MASTERCLASS:** Evidence-based Answers to 1000 Questions

- cerebrovascular disorders 383–58
- cervical cancer
 - risk, hormonal contraception 17
 - in young women 253–2
- cervical intraepithelial neoplasia (CIN) 512
- cervical smears/screening
 - clinical guidelines 267–9
 - incidental detection of bacteria 271–3
 - opportunistic chlamydia screening 270–1
 - plastic vs metal speculums 255
 - routine pelvic examination 269–70
 - in young women 252–4
- cervical weakness, history of 137
- cervix
 - cleansing, prior to IUD insertion 153
 - priming for IUD insertion 488
 - swabbing *see* microbiology testing
 - traction, at IUD insertion 153–4
- Charcot Marie Tooth syndrome 371
- chasteberry (*Vitex agnus castus*) 33–1
- Chinese steel ring intrauterine devices 217–18
- Chlamydia trachomatis
 - bacterial vaginosis and 188–9
 - infections in IUD users 164–6
 - prophylaxis, induced abortion 234
 - screening
 - opportunistic 270–1
 - prior to IUD insertion 145–6, 147, 186–7
 - treatment
 - before induced abortion 235
 - prior to IUD insertion 149
- chloasma 472–3
- chlorpheniramine, in anaphylaxis 103, 250
- cholangitis, primary sclerosing 52–3
- cholecystectomy 447–9, 516
- cholestasis
 - combined hormonal contraceptive-related 458
 - pregnancy-related 449–51
- cholesterol, high *see* hypercholesterolaemia
- chorea, oral contraceptive-induced 378–9
- ciclosporin 316–19, 465, 532–3
- Cilest®
 - in cardiomyopathy 410–12
 - venous thromboembolism risk 8–9
- cirrhosis of liver 456, 453–5
 - in porphyria 544
- clerical staff 252
- clinics, family planning, drop-in vs appointment 247–9
- clomifene citrate 285
- clotting studies, estrogen-containing
 - preparation users 279–80
- cocaine 340, 340–2
- colitis 448–9, 562–3
- colposcopy
 - Chinese steel ring IUD users 218
 - insertion of IUDs after 144–5
- combined hormonal contraception
 - 3–56
 - in breast cancer 484
 - cholestasis induced by 458
 - drug interactions 494
 - in haemophilia 527–8
 - in liver disease 453–4, 455
 - monthly injectables 216–17
 - oral *see* combined oral contraception
 - in thrombophilias 439, 441, 443–4
 - transdermal *see* combined transdermal contraception
 - in venous thromboembolism 433–4
 - see also* estrogen-containing preparations
- combined oral contraception 3–46
 - in achondroplasia 508
 - in acquired heart disease 410–12, 412–16
 - in acrocyanosis 503–4
 - in acute macular neuroretinopathy 369
 - adverse effects 8–9, 21–30
 - after induced abortion 237, 238

- after oral emergency contraception 13–14
- in anorexia nervosa 505–6
- in autoimmune cyclical neutropenia 509
- blood tests for gonadotrophins, thyroid function and clotting studies 279–80
- breast cancer risk 16, 489–90
- in cerebral palsy 52, 370–1
- in cerebrovascular disorders 384, 387, 390, 392–3
- choice of pill and starting regimens 7–15
- in congenital glaucoma 371–2
- in congenital heart disease 396, 397, 402–7
- in cystic fibrosis 515
- diagnosis of menopause 278, 279–80
- in DMPA users with abnormal bleeding 97, 98, 521
- drug interactions
 - antibiotics 311–5
 - anti-obesity medications 336, 337
 - complementary medicines 326–7, 326–7, 330–1
 - illegal recreational drugs 340, 341
 - liver-enzyme inducers 303, 305, 306, 494
 - retinoids 321, 477
 - tacrolimus 319–20
 - in tuberculosis 560–1
 - vitamin C 334
- in dysmenorrhoea 35–6
- efficacy 7–8, 9–14, 36–7
- in epilepsy 344, 345, 346, 348
- ‘every day’ pills 11–12, 37, 42, 43
- in gall bladder disease 447–8, 515–16
- in haemochromatosis 526–7
- in haemophilia 527–8
- HIV acquisition/transmission and 495–6
- in HIV infection 499, 500
- in hyperlipidaemia 392–3, 425–7, 423–4
- in idiopathic thrombocytopenic purpura 531, 532
- in ischaemic heart disease 417–18, 419–23
- in Kawasaki disease 533–4
- in lactose intolerance 534–5
- in liver disease 449–50, 452, 455–6, 457, 459
- managing problems during use 30–9
- in migraine 350–9, 357
- missed pills and potential failures 9–10, 36–7, 40–6, 232
- in multiple sclerosis 373–4
- in obesity 4–5, 36, 98, 121, 538
- in older women 5, 30–1, 277–9
- in otosclerosis 376–7
- in ovarian cancer 540–1
- past history of acoustic neuroma 368–9
- patient selection 3–6
- in pituitary tumours 366–7
- in polycystic ovary syndrome 542–3
- in porphyria 544–5
- in progestogen-only implant users 134
- in Raynaud’s phenomenon 548–50
- refusal to prescribe 261–3
- in renal disorders 463, 465–7, 469
- in rheumatoid arthritis 551
- risks and sequelae 16–21
- in Schamberg’s disease 552–3
- in sickle cell disease 554–6
- in skin disorders 472–3, 474–5, 476, 478–9
- skin disorders caused by 24–6, 472–3, 475, 481
- stroke risks *see* under stroke
- stroke while taking 386
- supply arrangements 251
- switching formulations 12–13
- switching to progestogen-only implants 124–5
- in Sydenham’s chorea 378–9
- in thrombophilias 436–7, 439, 443–4
- time-expired pills 44

Cambridge University Press

978-1-904-75233-2 - Family Planning Masterclass: Evidence-Based Answers to 1000 Questions

Gillian Penney, Susan Brechin and Anna Glasier

Index

[More information](#)**574 FAMILY PLANNING MASTERCLASS:** Evidence-based Answers to 1000 Questions

- ‘tricycling’ 37
 - in trophoblastic disease 559–60
 - in ulcerative colitis 562–3
 - in valvular heart disease 53, 397, 402–3
 - venous thromboembolism risks *see under* venous thromboembolism
 - vs combined transdermal contraception 46–7
 - combined transdermal contraception 46–8
 - drug interactions 494
 - in haemophilia 527–8
 - Combivir® 493–5
 - competence, IUD insertion 155
 - complementary medicines 325–32
 - compliance
 - failures, combined pill 9–10, 37–8, 40–3
 - strategies for improving 10, 259
 - condoms 205–6
 - back-up use *see* back-up
 - contraception/abstinence from sex
 - free provision 248
 - confidentiality
 - guidance on breaching 260
 - patients aged under 16 years 259
 - congenital abnormalities *see* fetal abnormalities
 - congenital heart disease 395–409
 - consent
 - written, for IUD insertion 257
 - young women under 16 years 258, 260, 385, 508–9
 - young women with learning difficulty 262–4
 - contact lenses 27–8
 - copper, intrauterine corrosion 141
 - Copper-7 IUD 172
 - copper intrauterine devices (IUDs) 136–81
 - after endometrial ablation 523–4
 - after induced abortion 143–4, 237, 239–42
 - in anticoagulated patients 391–2, 429, 433
 - antimicrobial prophylaxis for insertion/removal *see under* antimicrobial prophylaxis
 - in breast cancer 487–8
 - choice of device 139–42
 - complicated insertion 155–9
 - discontinuation or removal 174–81
 - efficacy 139
 - emergency use 222, 223, 228, 228
 - in epilepsy 344, 345
 - expired 161–2
 - expulsion 137, 155–6, 157–8, 168–9, 178
 - failed insertion 487–8
 - follow-up 163–4, 251
 - in heart disease 396, 397, 401, 429–31
 - in HIV infection 499, 501, 532–3
 - in immunocompromised patients 532–3
 - investigations prior to insertion 145–9
 - in liver disease 454–5, 459–60
 - lost threads 158–9, 170, 178
 - misplacement 168–70
 - patient selection 136–8
 - problems at insertion 159–3
 - problems during use 164–74, 274
 - recall systems for removal 257–9
 - routine insertion procedures 149–56
 - in skin lesions 479
 - timing of insertion 142–5
- Copper T380A IUD 160, 171–2
- coronary artery bypass 418–19
 - coronary artery stenting 418–19, 430–1
 - coronary heart disease *see* ischaemic heart disease
 - corticosteroid therapy 514
 - in Addison’s disease 504–5
 - high-dose, in IUD users 168
 - in Takayasu arteritis 380–1, 563
 - in ulcerative colitis 562–3
 - cost-effectiveness
 - free condoms 248

- progestogen-only emergency contraception 260–1
- Crohn's disease 512–14
- Cushing's disease 366
- Cushing syndrome 514
- cutaneous lupus erythematosus 26
- cyanotic congenital heart disease 407–8
- cyclical neutropenia, autoimmune 509
- Cyclofem® 216–17
- cyclophosphamide 563
- Cyklokapron® 193
- cypoterone acetate-containing pill *see* Dianette®
- cystic fibrosis 515–16
- decompression sickness 19
- deep vein thrombosis (DVT) *see* venous thromboembolism
- deltoid muscle, DMPA injections 99
- dental problems 23
- depot medroxyprogesterone acetate (DMPA) (Depo-Provera®) 82–113
 - abnormal bleeding 96–8, 115, 521
 - administration 98–100, 104
 - adverse effects 22, 23, 108–13, 535
 - after induced abortion 238–9
 - anaphylactic and allergic reactions 100–5
 - in Asperger syndrome 510–12
 - in bipolar affective disorder 510–12
 - bone mineral density and 84–6, 90–6, 114
 - in cerebrovascular disorders 386–7
 - in Crohn's disease 512–14
 - in diabetes 521–2
 - dose and regimens 105–7
 - drug interactions 299, 301, 309–11, 322–3, 335–6
 - in endometriosis 530
 - in epilepsy 344, 346–7, 349
 - in heart disease 396, 425, 427–8
 - in HIV infection 495, 497–8, 500
 - interval between injections 98, 100, 105, 106, 106–7
 - in Legg-Calve-Perthes disease 535–6
 - in liver disease 456
 - LNG-IUS in peritoneal cavity 191
 - in migraine 354–5, 357–8
 - in obesity 82, 97–8, 99, 538
 - in osteogenesis imperfecta 541
 - in ovarian cysts 541
 - patient selection 82–90
 - in polycystic ovary syndrome 547
 - in prolactinoma 365–6
 - in renal disorders 466, 467–8
 - in retinoblastoma 377–8
 - in rheumatoid arthritis 552
 - in Scheuermann kyphosis 554
 - in sickle cell disease 554–6
 - in smokers 31, 92–4
 - switching to norethisterone enanthate 113–14
 - in tuberculosis 561
- depression
 - in DMPA users 110–11, 510–12
 - metformin therapy in PCOS and 291–2
- dermatomyositis 474
- desmopressin 563–4
- desogestrel 198
- desogestrel-containing combined pills 7
 - acne recurrence and 56
 - adverse effects 8, 9
 - breakthrough bleeding 32–3
 - cardiovascular risk factors and 420
- desogestrel-only pill (Cerazette®)
 - abnormal bleeding patterns 69, 70
 - in benign intracranial hypertension 361
 - bone mineral density and 65
 - efficacy 72–3, 74–5
 - elective surgery 64
 - missed pills 78–9
 - in obesity 59, 121
 - ovarian cyst risk 68–9
 - pregnancy risk after stopping 75
 - in renal disorders 464–5
 - in rheumatoid arthritis 552

Cambridge University Press

978-1-904-75233-2 - Family Planning Masterclass: Evidence-Based Answers to 1000 Questions

Gillian Penney, Susan Brechin and Anna Glasier

Index

[More information](#)**576 FAMILY PLANNING MASTERCLASS:** Evidence-based Answers to 1000 Questions

- vaginal estrogens with 80
- warfarin and 338
- DEXA scanning 88, 90, 92
- diabetes
 - insulin-dependent
 - and Addison's disease 522–3
 - and high BMI 521
 - type II, and Down syndrome 522
- diabetic nephropathy 469
- Dianette® (cypoterone acetate-containing pill) 48–56
 - after acoustic neuroma 369
 - indications 27, 49, 50, 53–4
 - in PCOS and congenital heart disease 402–3
 - prevention of alopecia 22
 - venous thromboembolism risk 9, 49, 50–1
- diaphragms 206–8
 - in valvular heart disease 397
- diathermy treatment, Chinese steel ring IUD users 218
- diazepam 250
- diclofenac sodium 335
- dihydrotestosterone 21
- discoid lupus erythematosus 478–9
- dispensing arrangements 251–2
- diving, deep-sea 19
- DMPA *see* depot medroxyprogesterone acetate
- Down syndrome
 - competence to give consent 262–4
 - type II diabetes and 522
- doxycycline 317
- drop-in clinics 247–9
- drospirenone/ethinylestradiol combined pill (Yasmin®) 9
 - body weight changes 33–4
 - hirsutism and 27
 - in polycystic ovary syndrome 542–3
- drug interactions 299–42
 - complementary medicines 325–32
 - in HIV infection 493–5, 501
 - illegal recreational drugs 339–42
 - immunosuppressants 316–21
 - liver enzyme-inducers 299–11
 - liver enzyme-inducing antibiotics 309–10
 - miscellaneous 335–42
 - non-liver enzyme-inducing antibiotics 311–5
 - retinoids 321–5
 - in tuberculosis 560–1
 - drug use, illicit recreational 339–42
- dry-eye syndrome 28
- dural sinus thrombosis, postnatal 391–2
- dysmenorrhoea
 - in adolescents 35–6
 - adverse effects of NSAIDs 290–1
 - nephrotic syndrome with 465–7
- ear disease 376–7
- eating disorders 505–6
- ecstasy 340–2
- ectopic pregnancy
 - copper IUD or LNG-IUS after 136–7
 - Dianette® and 51
 - DMPA users 111–12
 - progestogen-only implants and 125
- Ehlers-Danlos syndrome 519–20
- electrolysis kits, home 171
- embolism, paradoxical 396
- emergency contraception
 - after progestogen-only implant removal 128
 - copper IUDs 222, 223, 228, 231
 - extended pill-free interval 44–5
 - late DMPA injections 106–7
 - late norethisterone acetate injections 116
 - missed combined pills 42, 43, 232
 - missed progestogen-only pills 77–9
 - progestogen-only *see* progestogen-only emergency contraception
 - time-expired combined pills 44
 - see also* back-up contraception/abstinence from sex
- emergency situations

- equipment and supplies (shock pack) 249–51
- LNG-IUS removal 187–8
- see also* anaphylactic reactions; resuscitation
- endocarditis
 - past history, IUD insertion/removal 407–8
 - prophylaxis
 - etonogestrel implant insertion/removal 403–4
 - female sterilisation 398
 - IUD or LNG-IUS insertion/removal 157–8, 189–90, 397, 407–8
- endocervical brush, cervical smears 268
- endometrial ablation, microwave 528–9
- endometrial cancer, postmenopausal
 - retention of IUDs and 178–9, 179, 205
- endometrial protection 80, 282–3
- endometriosis 131–2, 524–5
- epilepsy 343–9
 - catamenial 343
 - plus multiple other pathologies 425–7
 - see also* anticonvulsant drugs
- epinephrine (adrenaline) 250
 - in anaphylaxis 103, 250
- erectile dysfunction, and solvent abuse 293
- erythema multiforme major 475
- erythema nodosum 480–1
- erythromycin 314
- erythropoietic protoporphyria 545
- Essure® 209–12
- estradiol
 - monthly injectables 216
 - serum concentrations
 - DMPA users 93–4, 106
 - LNG-IUS users 197
- estrogen
 - conjugated, in migraine 357–8
 - dose, combined pills
 - in epilepsy 346
 - see also* ethinylestradiol dose, combined pills
 - natural, in migraine 357
 - receptor positive breast cancer 486
 - topical vaginal *see* vaginal estrogens, topical
- estrogen antagonist, nonsteroidal (centchroman) 219–20
- estrogen-containing preparations
 - in benign intracranial hypertension 360
 - clotting studies 279–80
 - illegal recreational drug users 340, 341–2
 - in multiple pathologies 425–7
 - serum gonadotrophin tests 134–5, 278, 279–80
 - thyroid function tests 279–80
 - see also* combined hormonal contraception; hormone replacement therapy
- estrogen replacement therapy
 - DMPA users 93–4, 95
 - with LNG-IUS 282–3
 - in migraine 357–8
 - post-pill amenorrhoea 20
- ethambutol 309–11, 561
- ethical issues 257–64
- ethinylestradiol dose, combined pills
 - antibiotic users 46
 - breakthrough bleeding and 32–3
 - in epilepsy 346
 - in HIV infection 500
 - in hypercholesterolaemia 422–3
 - missed pill rules in relation to 41–3
 - in obesity 539
 - optimal 7–8, 9, 10
 - switching 12–13
- ethinylestradiol–norelgestromin patch (Evra®) 47
 - see also* combined transdermal contraception
- ethnic minorities, walk-in style services 247, 248

Cambridge University Press

978-1-904-75233-2 - Family Planning Masterclass: Evidence-Based Answers to 1000 Questions

Gillian Penney, Susan Brechin and Anna Glasier

Index

[More information](#)**578 FAMILY PLANNING MASTERCLASS:** Evidence-based Answers to 1000 Questions

- etonogestrel-releasing implant (Implanon®)
 - adverse effects 129–32
 - in anticoagulated patients 411–12, 438–9
 - in cerebrovascular disorders 387–3, 389–90
 - drug interactions 300–1, 323–5, 331, 341–2
 - efficacy 120–2, 125
 - endocarditis prophylaxis for insertion/removal 403–4
 - in epilepsy 345, 349
 - in fibrodysplasia ossificans progressiva 525–6
 - in gall bladder disease 448–9
 - in HIV infection 493–5
 - insertion and removal 125–6, 127, 128
 - in liver disease 456, 458–9
 - in migraine 357
 - in obesity 117, 118–19, 121–2
 - in older women 119
 - in renal disorders 473
 - in rheumatoid arthritis 552
 - in skin disorders 481–2
 - unscheduled bleeding 132–4
 - see also* progestogen-only implants
- etoricoxib (Arcoxia®) 552
- etretinate 325
- etynodiol diacetate 198
- etynodiol diacetate-only pill
 - missed pills 76–7
 - in obesity 58–9
 - pregnancy risk after stopping 75
- Eugynon 30® 56
- evening primrose oil 287–9
- Evra® 47
 - see also* combined transdermal contraception
- experience, clinician, IUD insertion 153–4
- expired combined pills 44
- expired intrauterine devices 161–2
- eye diseases 369, 371–2
- facial numbness
 - occasional, and migraine 351–2
 - transient, DMPA users 112–13
- factor V Leiden deficiency 437–9
- family planning services *see* services, family planning
- female sterilisation 209–12
 - after induced abortion 242
 - LNG-IUS as alternative 180–1
 - obese women awaiting 121–2
 - in valvular heart disease 397–8
- Femodene® ED 12
- Femodette® 32
- Femulen® 540
- fenofibrate 423
- fenoprofen 291
- fertility awareness-based methods 214–15
- fetal abnormalities
 - combined pill users 14, 37–8
 - DMPA users 112
- fibrodysplasia ossificans progressiva 525–6
- fibroids, uterine, LNG-IUS use 203–4
- fistula, anovaginal 506
- flecainide acetate 413–14
- Flexi-T300 IUD 140
- flucloxacillin 311–12
- fluconazole 315
- fluid retention, benign intracranial
 - hypertension and 361
- flushes, hot *see* menopausal symptoms
- focal nodular hyperplasia of liver 462
- follicle-stimulating hormone (FSH), serum 278
 - DMPA users 86, 522
- estrogen-containing preparation users 135, 278, 279–80
- IUD users 174, 202–3
- progestogen-only pill users 62, 279
- tamoxifen users 283–4
- follow-up arrangements 251
- fractures, osteoporotic 92–4
- Fraser guidelines (1985) 258, 260, 385

- furosemide 514
- gall bladder disease 447–9, 516
- gamma linolenic acid 289, 331
- gemeprost, medical abortion 238
- general anaesthesia, removal of Chinese steel ring IUDs 217–18
- general practitioners, prescribing of IUDs 263–5
- genital herpes, recurrence in IUD users 166–7, 195–6
- genital tract infections
 LNG-IUS insertion after 181–3
 prophylaxis *see* antimicrobial prophylaxis
 see also pelvic infections; sexually transmitted infections
- gestodene-containing combined pills 7
 adverse effects 8, 9
 breakthrough bleeding 32–3
 cardiovascular risk factors and 420
- Gilbert's disease 455–6
- Gillick vs West Norfolk and Wisbech Area Health Authority (1986) 385, 508–9
- gingivitis 23
- girls *see* adolescents
- glaucoma, congenital 371–2
- gluteal muscle, DMPA injections 99
- gonadotrophin-releasing hormone (GnRH) agonists
 and add-back HRT, for endometriosis 524–5
 combined with tamoxifen 284–5
- gonadotrophins, serum
 estrogen preparation users 279–80
 tamoxifen users 283–4
 see also follicle-stimulating hormone (FSH), serum
- gonorrhoea *see* Neisseria gonorrhoea
- grapefruit juice 334, 550
- griseofulvin 45–6, 307
- group A streptococcus 148, 271
- group B streptococcus 148, 271
- guardians, consent by 262, 509
- gum disease 23
- gynaecological problems 265–95
- GyneFix® IUD 140, 141, 159–60
- haemochromatosis 526–7
- haemodialysis 463–4
- haemolytic-uraemic syndrome 356
- haemophilia 527–8
- hair loss 21–2
- health visitors 252
- heart disease 53–4, 395–432
 acquired 409–32
 congenital 395–409
 ischaemic *see* ischaemic heart disease
- heart transplant recipients 415–16
- HELLP syndrome 452–3
- hemiparesis 389–90
- Henoch-Schönlein purpura 528
- heparin, progestogen-only implants and 438–9
- hepatitis 458–61
 acute, combined pill-associated 458
 viral 456, 458–60
- hepatitis A 458–9
- hepatitis B 459–60
- hepatitis C 460
- herbal remedies 325–32
- herpes, genital, recurrence in IUD users 166–7, 195–6
- high altitude 18
- highly active antiretroviral therapy (HAART) 495
 see also antiretroviral drugs
- hirsutism
 Dianette® therapy 27, 49, 50–1, 53–4
 LNG-IUS use and 198–9
 in polycystic ovary syndrome 547, 543
- HIV infection 493–502
 antiretroviral drug interactions 493–6, 499–501
 bone mineral density and 497–8
 free provision of condoms 248
 IUD use 501, 532–3

Cambridge University Press

978-1-904-75233-2 - Family Planning Masterclass: Evidence-Based Answers to 1000 Questions

Gillian Penney, Susan Brechin and Anna Glasier

Index

[More information](#)

580

FAMILY PLANNING MASTERCLASS: Evidence-based Answers to 1000 Questions

- nonoxynol-9 use and 206
- risk of acquiring/transmitting 495–6
- home
 - electrolysis kits 171
 - LNG-IUS removal at 187–8
- hormone replacement therapy (HRT)
 - add-back, with GnRH, for endometriosis 524–5
 - alternatives to 281
 - blood tests for gonadotrophins, thyroid function and clotting studies 279–80
 - LNG-IUS for progestogen component 282–3
 - in otosclerosis 376–7
 - personal/family history of VTE and 281
 - progestogen-only implants with 134–5
 - progestogen-only pill with 79–80, 81 *see also* estrogen replacement therapy
- hot flushes *see* menopausal symptoms
- HRT *see* hormone replacement therapy
- human chorionic gonadotrophin (hCG), serum 265–6, 559, 560
- human immunodeficiency virus *see* HIV
- hydatidiform mole 558–60
- hydrocortisone 250
 - in anaphylaxis 103, 250
 - long-term therapy 514
- hypercholesterolaemia 422–5
 - familial 423–4
 - fenofibrate-treated 423
 - plus family history of stroke 392–3
- Hypericum perforatum (St John's wort) 325–30
- hyperlipidaemia 420–4
 - plus family history of stroke 392–3
 - in renal disease 317–18, 318, 464
- hypermobility syndrome 354
- hyperprolactinaemia 20, 363–6
- hypertension
 - adequately controlled 417
 - cerebrovascular disease and 387
 - contraindicating combined pill 3, 19
 - DMPA use 427–8, 433
 - in neurofibromatosis 375
 - pill-induced 19
 - refusal to prescribe combined pill 261–3
 - renal disorders with 463, 464–5, 467–8
 - sibutramine hydrochloride and 336, 337
- hyperthyroidism 309–11
- hypothyroidism 448–9
- hysteroscopy
 - IUD identification 178
 - tubal occlusion (Essure®) 209–12
- idiopathic thrombocytopenic purpura 530–2
- illegal recreational drugs 339–42
- immunocompromised women 532–3
- immunoglobulin A (IgA) nephropathy 23–4
- immunosuppressants 316–21
 - in dermatomyositis 474
 - IUD insertion and 532–3
 - in Takayasu arteritis 380–1, 563
 - in transplant recipients 319, 415–16, 461, 465
- Implanon® *see* etonogestrel-releasing implant
- indomethacin 291
- induced abortion 233–44
 - hormonal contraception after 237–8
 - insertion of IUDs after 143–4, 235, 237–8, 239–42
 - medical, regimens 235–6
 - sterilisation after 242
- infections
 - in IUD users 164–8
 - prophylaxis *see* antimicrobial prophylaxis
 - testing for *see* microbiology testing
 - treatment prior to IUD insertion 147–9

- see also* genital tract infections; pelvic infections; sexually transmitted infections
- inflammatory bowel disease 52
- combined oral contraception 562–3
- progestogen-only contraception 448–9, 498, 512–14
- injectable contraceptives
- monthly 216–17
- progestogen-only *see* progestogen-only injectables
- interferon 460
- intermenstrual bleeding
- progestogen-only pill 69–71
- smokers aged over 35 years 30–1
- intracranial aneurysms 383–4
- intracranial haemorrhage 383–5
- intracranial hypertension, benign 359–63, 425–7
- intrauterine contraception (IUDs) 136–205
- actinomyces-like organisms in cervical smears 272–3
- after endometrial ablation 523–4
- in anovaginal fistula 506
- anticoagulated patients 391–2, 433–4, 435
- antimicrobial prophylaxis for insertion/removal *see* under antimicrobial prophylaxis
- in Asherman syndrome 506–7
- Chinese steel ring 217–18
- in congenital heart disease 397, 405–6
- consent for insertion 257
- copper *see* copper intrauterine devices
- endocarditis prophylaxis for insertion/removal *see* under endocarditis
- follow-up 163–4, 251
- in HIV infection 501, 532–3
- insertion after induced abortion 143–4, 235, 237–8, 239–42
- in ischaemic heart disease 433–6
- prescribing by general practitioners 263–5
- recall systems for removal 257–9
- in trophoblastic disease 564
- intrauterine system, levonorgestrel-releasing *see* levonorgestrel-releasing intrauterine system
- ischaemic heart disease 109, 417–32
- after coronary artery bypass and stenting 418–19
- family history 417–18, 420–1
- risk factors *see* cardiovascular risk factors
- women at increased risk 419–23, 427–8
- women with current disease 424–7, 433–6
- isoniazid 561
- isotretinoin 321–3, 477
- itraconazole 317
- IUDs *see* copper intrauterine devices; intrauterine contraception
- Jadelle® 123, 129
- joint hypermobility 354
- Kawasaki disease 533–4
- ketoconazole 317
- Klippel-Trenaunay-Weber syndrome 445
- kyphosis, Scheuermann 553–4
- lactational amenorrhoea 60
- lactose intolerance 534–5
- Lamictal® 348
- Lamisil® 333
- lamivudine 493–5
- lamotrigine 347–8
- lansoprazole 306–8
- large loop excision of the transformation zone (LLETZ) 144
- laser surgery, cardiac 415
- learning difficulties
- competence to give consent 262–4
- service provision 251
- legal issues 257–64

Cambridge University Press

978-1-904-75233-2 - Family Planning Masterclass: Evidence-Based Answers to 1000 Questions

Gillian Penney, Susan Brechin and Anna Glasier

Index

[More information](#)

582

FAMILY PLANNING MASTERCLASS: Evidence-based Answers to 1000 Questions

- Legg-Calve-Perthes disease 535–6
- letter of competence in intrauterine techniques (LoC IUT) 155
- levofloxacin 274
- Levonelle, vs generic levonorgestrel 260–1
- levonorgestrel
 - androgenic effects 198
 - in combined pills 7, 8–9, 56, 420
 - emergency contraception *see*
 - progestogen-only emergency contraception
 - generic vs branded, for emergency contraception 260–1
- levonorgestrel-only pill
 - efficacy 72–3, 74–5
 - missed pills 76
 - in obesity 58–9
 - pregnancy risk after stopping 74–5
- levonorgestrel-releasing implant (Norplant®)
 - adverse effects 22, 129, 531
 - efficacy 122–3
 - in obesity 58, 117
 - removal 126–7
- levonorgestrel-releasing intrauterine system (LNG-IUS) 180–203
 - after surgical abortion 239–40
 - anaphylaxis risk 102, 187–8, 190
 - in anticoagulated patients 391–2, 433–5
 - in benign intracranial hypertension 362–3
 - in breast cancer 484–5, 486–7
 - in cardiovascular disease 396, 397, 401, 418–19, 433, 430–1
 - in cerebrovascular disorders 385–6, 388–90, 433
 - combined with Dianette® 54–5
 - continuation and removal 175, 201–4
 - drug interactions 305–6, 477
 - liver-enzyme inducers 494
 - in tuberculosis 561
 - effectiveness 180–1
 - in Ehlers-Danlos syndrome 520
 - endocarditis prophylaxis for insertion/removal *see* under endocarditis
 - in epilepsy 344, 345
 - in erythropoietic protoporphyria 545
 - expulsion 157–8, 168–9
 - extrauterine location 191
 - in HIV infection 499, 501
 - in inflammatory bowel disease 513
 - insertion 142–3, 187–91
 - complicated 157, 157–8
 - investigations before 186–7
 - in migraine 355–6
 - misplacement 168–70
 - patient selection 31, 136–7, 140, 178–9, 181–7
 - prescribing by general practitioners 263–5
 - problems during use 166–7, 192–200, 274
 - for progestogen component of HRT 282–3
 - in prolactinoma 364–5
 - recall systems for removal 257–9
 - in renal disorders 464–5, 466–7
 - in rheumatoid arthritis 551–2
 - in skin disorders 480
 - in thrombophilias 441–2, 443
 - in von Willebrand's disease 563–5
- libido, decreased 129–30
- lichen sclerosis 476–7
- life table analysis 181
- lipids, serum
 - combined pill formulations and 8
 - oral vs transdermal contraception 47
 - see also* hypercholesterolaemia; hyperlipidaemia
- liposarcoma 536
- Lippes Loop IUD 172, 177, 179
- liver disease 447–62
 - progestogen-only implants 130, 456, 458–9
 - in sickle cell disease 555, 556
- liver-enzyme inducers 299–11

Cambridge University Press

978-1-904-75233-2 - Family Planning Masterclass: Evidence-Based Answers to 1000 Questions

Gillian Penney, Susan Brechin and Anna Glasier

Index

[More information](#)

- antibiotics 309–10
- anti-epileptics 343–4
- antiretrovirals 493–5, 495, 499–501
- antituberculous drugs 561
- herbal remedies 329–30
- St John's wort 325–30
- liver transplant recipients 461
- liver tumours, benign 462
- LNG-IUS *see* levonorgestrel-releasing intrauterine system
- Loestrin® 32, 540
- Logynon® 12, 56
- loin pain haematuria syndrome 23–4
- lumboperitoneal shunt 425–7
- lumps, around DMPA injection site 104
- Lunelle® 216–17
- lung transplant, women awaiting 305–6
- lupus anticoagulant 26, 440, 441
- lupus erythematosus
 - cutaneous (CLE) 26
 - discoid 478–9
 - systemic *see* systemic lupus erythematosus
- macrolide antibiotics 313–14
- macroprolactinaemia 364, 364–5
- macular neuroretinopathy, acute 369
- magnetic resonance imaging (MRI), IUD users 171–2
- maladie de Roger 401–2
- malaria prophylaxis 314–15
- male sterilisation 212–13
- manic-depressive illness 510–12
- Marfan syndrome 399–400
- Marvelon® 33
- medical problems, complex 137–8, 425–7
- medico-legal issues 257–64
- medroxyprogesterone acetate
 - depot *see* depot medroxyprogesterone acetate
 - effect on prolactin levels 365–6
 - in epilepsy 343
 - monthly injectables 216
- mefenamic acid 193, 291
- melasma 472–3
- Meliane® 33
- menarche 276
- meningitis, cerebral infarcts after 390
- menopausal symptoms
 - copper IUD users 174–5
 - efficacy of progestogens 280–1
 - LNG-IUS users 203
 - progestogen-only contraception and 81, 122–3, 134–5, 279
 - see also* perimenopause
- menopause 276–87
 - diagnosis 278–9
 - DMPA users 86, 522
 - estrogen preparation users 134–5, 279–80
 - IUD users 174–5, 202–3
 - progestogen-only pill users 61–2, 279
 - tamoxifen users 283–4
- premature, Shwachman–Diamond syndrome 287
- menorrhagia
 - in anticoagulated patients 434–5
 - combined oral contraception 31, 36
 - in haemophilia 527–8
 - in idiopathic thrombocytopenic purpura 531–2
 - LNG-IUS 181–5, 192
 - in prolactinoma 364–5
- management options 193
- nephrotic syndrome with 465–7
- norethisterone therapy 289–90
- pemphigoid gestationis and 480
- stroke and valvular heart disease and 406
- in von Willebrand's disease 563–4
- menstrual cycle(s)
 - after menarche 276
 - catamenial epilepsy 343
 - insertion of IUDs 143
 - porphyria exacerbations 544
 - repeat progestogen-only emergency contraception 229–31

Cambridge University Press

978-1-904-75233-2 - Family Planning Masterclass: Evidence-Based Answers to 1000 Questions

Gillian Penney, Susan Brechin and Anna Glasier

Index

[More information](#)

- starting hormonal contraception
 - 10–12, 125
- menstrual problems 287–90
 - see also* bleeding patterns, abnormal;
 - dysmenorrhoea; menorrhagia
- menstruation
 - delaying
 - Dianette® users 55
 - DMPA users 115
 - progestogen-only pill users 72
 - insertion of IUDs 143
- Mercilon® 32–3
- Mesigyna® 216–17
- mestranol 7
 - in epilepsy 346
- metabolic problems, transdermal
 - contraception 46–7
- metformin 291–5
- methicillin-resistant *Staphylococcus aureus* (MRSA)
 - eradication, LNG-IUD users 194–5
 - identified on vaginal swabs 273–4
 - in IUD users 166–7, 274
- methotrexate 335, 381, 552, 563
- metronidazole 274, 313–14
- metypapone 514
- microbiology testing
 - cervical cytology 270–4
 - induced abortion 233–4
 - prior to IUD insertion 145–7, 186–7
 - Staphylococcus aureus* identified on 273–4
- Microgynon® 11–12, 23, 56
- Micronor® 23, 290
- Microval, emergency contraception 261
- midwives 252
- mifepristone (Mifegyne®), medical
 - abortion 235–6
- migraine 350–9
 - abdominal 351
 - with aura 350, 389
 - with focal symptoms 351–2, 353–8, 389
 - and occasional facial weakness 351–2
 - during pill-free interval 352–3
 - without aura 350
- Mirena® *see* levonorgestrel-releasing
 - intrauterine system
- miscarriage, IUD insertion after 240
- misoprostol
 - cervical priming for IUD insertion 488
 - interactions 335
 - medical abortion 238
- missed pill rules 41–3, 77, 232
- mitral valve prolapse 402–3
- ML 375 IUD 140
- molar pregnancy 558–60
- monthly injectable contraception 216–17
- mood disturbances/swings
 - in DMPA users 110–11, 510–12
 - metformin in PCOS 291–3
 - premenstrual 287–9
- mood stabilisers 510–12
- MRSA *see* methicillin-resistant
 - Staphylococcus aureus*
- Multiload® Cu 375 IUD 155
- multiple sclerosis (MS) 372–4
- mycophenolate mofetil 461
- myocardial infarction
 - past history
 - and coronary artery stent 430–1
 - and multiple other pathologies 425–7
 - and warfarin therapy 433–4
 - risks, combined pill 8, 30–1, 420–1
- naproxen 291
- National Institute for Clinical Excellence (NICE) 85–6, 87, 210
- natural family planning methods 214–15
- Neisseria gonorrhoea*
 - bacterial vaginosis and 188–9
 - prophylaxis, induced abortion 234
 - screening prior to IUD insertion 145–6, 147, 186–7
 - treatment prior to IUD insertion 149

Cambridge University Press

978-1-904-75233-2 - Family Planning Masterclass: Evidence-Based Answers to 1000 Questions

Gillian Penney, Susan Brechin and Anna Glasier

Index

[More information](#)

- nephrotic syndrome 318–19, 465–7
- neurofibromatosis 374–5
- neurological disorders 343–94
- neurosurgical procedures 34–5
- neutropenia, autoimmune cyclical 509
- NHS Cervical Screening Programme (NHSCSP) 252–4
- nifedipine 550
- nipple discharge 22
- non-licensed contraceptive methods 215–21
- nonoxynol-9
 - condoms lubricated with 205–6
 - spermicides not containing 207–8
- non-steroidal anti-inflammatory drugs (NSAIDs)
 - abnormal bleeding 134, 193
 - adverse effects in dysmenorrhoea 290–1
 - in rheumatoid arthritis 552
- norethindrone 198
- norethisterone
 - in combined pills 7, 8, 9, 32, 420
 - to delay bleeding, progestogen-only pill users 72
 - for menorrhagia, contraceptive efficacy 289–90
 - monthly injectables 216
- norethisterone enanthate 113–16
- norethisterone-only pill
 - missed pills 76–7
 - in obesity 58–9
 - pregnancy risk after stopping 75
- norethynodrel 7
- norgestimate 8–9, 198
- Norgeston®, emergency contraception 261
- norgestrel 198
- Noriday® 290
- Norimin® 466
- Norinyl-1® 346
- Norplant® *see* levonorgestrel-releasing implant
- Nova T® 200 IUD 140
- Nova T® 380 IUD (previously Novagard®) 137–8, 140, 160
- Nova TT380S IUD 139, 140
- nurses, extended role 251–2
- Nuvaring® 215–16
- obesity 537–9
 - benign intracranial hypertension and 361
 - combined oral contraception 4–5, 36, 98, 121, 538
 - contraception while awaiting sterilisation 121–2
 - drug interactions 303–4, 335–8
 - insulin-dependent diabetes and 521
 - progestogen-only emergency contraception 223
 - progestogen-only implants 116–19, 121–2, 539
 - progestogen-only injectables 82, 97–8, 99, 538
 - progestogen-only pill 58–60, 74, 121, 538–9
 - retinoid users 324–5
- ofloxacin 274
- older women
 - Charcot Marie Tooth syndrome 371
 - combined oral contraception 5, 30–1, 277–9
 - continuation of contraception 277–9
 - copper IUDs 174–5, 176–9
 - high cholesterol and family history of stroke 392–3
 - IUDs in extrauterine position 173, 178
 - LNG-IUS 202–4
 - pregnancy risks 277
 - progestogen-only emergency contraception 224–5
 - progestogen-only implants 119, 122–3, 134–5
 - progestogen-only injectables 86–8, 90–1
 - progestogen-only pills 60–2, 73, 79–80, 81

Cambridge University Press

978-1-904-75233-2 - Family Planning Masterclass: Evidence-Based Answers to 1000 Questions

Gillian Penney, Susan Brechin and Anna Glasier

Index

[More information](#)

- on retinoids 324
- stopping contraception 61, 278
- see also* menopause; perimenopause; postmenopausal women
- oral contraceptives
 - centchroman (weekly nonsteroidal) 219–20
 - combined *see* combined oral contraception
 - prescribing for young women under 16 years 258–60
 - progestogen-only *see* progestogen-only pill
- organisation of family planning services *see* services, family planning
- orlistat 337–8
- Orthogyn T (Gyne T380S) IUD 178–9
- orthopaedic surgery, elective 64
- osteogenesis imperfecta 539–40
- osteopenia
 - in HIV infection 498
 - progestogen-only injectables and 92, 95
 - see also* bone mineral density
- osteoporosis
 - in anorexia nervosa 510
 - desogestrel-only pill and 65
 - in inflammatory bowel disease 512–14
 - LNG-IUS and 198
 - multiple pathologies with 448–9
 - post-pill amenorrhoea 20
 - primary biliary cirrhosis and 455
 - progestogen-only implants and 130–1, 198
 - progestogen-only injectables and 87–8, 92–4, 95
 - risk factors 92–4
- otosclerosis 376–7
- ovarian cancer, past history 540–1
- ovarian cysts, benign functional 67–9, 541
- ovarian failure, premature 20
- overweight *see* obesity
- Ovran® 346, 500
- Ovranette® 56
- ovulation
 - after extended combined pill-free interval 44–5
 - after progestogen-only implant removal 128
 - after starting combined hormonal contraception 10–11
 - before/after menarche 276
 - Calista® saliva test 214–15
 - progestogen-only pill users 74–5, 79–80
 - resumption after DMPA injections 105, 105–6
- oxygen treatment
 - in anaphylaxis 103, 250
 - vasovagal episodes at IUD insertion 162
- paramedics 252
- parents
 - consent by 260, 262, 263, 508–9
 - disclosure of information to 260
- Patient Group Directions 251–2
- PCOS *see* polycystic ovary syndrome
- Pearl index 7, 36, 58, 73, 125, 180
- pelvic examination
 - guidance 269–70
 - at routine cervical screening 269–70
- pelvic infections
 - insertion of IUDs after 144
 - prophylaxis *see* antimicrobial prophylaxis
 - testing for *see* microbiology testing
 - treatment prior to IUD insertion 147–9
 - see also* sexually transmitted infections
- pelvic inflammatory disease (PID)
 - anovaginal fistula and 506
 - high-dose steroid therapy and 168
 - in IUD users 164–6
 - methicillin-resistant *Staphylococcus aureus* and 166–7
 - oral antibiotic regimens 274

Cambridge University Press

978-1-904-75233-2 - Family Planning Masterclass: Evidence-Based Answers to 1000 Questions

Gillian Penney, Susan Brechin and Anna Glasier

Index

[More information](#)

- treatment prior to IUD insertion 148–9
- pemphigoid gestationis 480
- penicillin 312
- penicillin V 314
- perimenopause
 - continuing contraception 277–9
 - copper IUDs 174–5, 176, 178–9
 - LNG-IUS 202–3
 - progestogen-only implants 122–3, 134–5
 - progestogen-only injectables 86–8, 522
 - progestogen-only pill 60–2, 81, 279
 - stopping contraception 61, 278
 - see also* menopause
- pharmacists 252
- phenytoin 300
- pituitary tumours 363–8
- pityriasis versicolor 481–2
- polycystic kidney disease 467–8
- polycystic ovary syndrome (PCOS) 20, 49, 541–3
 - and congenital heart disease 402–3
 - LNG-IUS users 54–5
 - metformin therapy 291–3
- polymyositis 448–9
- porphyria 543–5
- postcoital bleeding, IUD users 171
- postmenopausal women 280–3
 - with IUDs in place 176–8, 179
 - uterine fibroids, and LNG-IUS 203–4
 - vasomotor symptoms *see* menopausal symptoms
 - see also* hormone replacement therapy; menopause; perimenopause
- postpartum period
 - combined oral contraception 6, 36–7, 368–9
 - IUD insertion 142–3, 155–6
 - progestogen-only emergency contraception 222–3
 - progestogen-only injectables 83–4
 - progestogen-only pill 59–60
- povidone iodine (Betadine), intravaginal 152, 153
- pregnancy
 - avoiding starting combined pill during 13–14
 - chloasma 472–3
 - cholestasis of 449–51
 - continuing combined oral contraception in 14, 37–8
 - criteria for determining absence 13
 - deep-sea diving 19
 - during DMPA use 112
 - in IUD or LNG-IUS users 175
 - molar 558–60
 - pemphigoid gestationis 480
 - risks in older women 277
 - testing 265–6
 - unintended, while using contraception 9–10
- premenstrual syndrome (PMS)
 - progestogen-only implants 131–2
 - symptoms 287–8
 - treatment 287–9
- prescription
 - IUDs by general practitioners 263–5
 - refusal, patients with contraindications 261–3
- primary biliary cirrhosis 454–5
- primary sclerosing cholangitis 52–3
- progestogen-only contraception 57–135
 - after venous thromboembolism 433–4, 435–6
 - anaphylaxis risk 102
 - in benign intracranial hypertension 361–2
 - in breast cancer 484–7, 488
 - breast cancer risk 65–7, 108–9, 490–2
 - in cerebrovascular disorders 384–8
 - in cervical intraepithelial neoplasia 512
 - in congenital heart disease 395–6, 397, 405–6
 - in Crohn's disease 512–14
 - in cystic fibrosis 515–16

Cambridge University Press

978-1-904-75233-2 - Family Planning Masterclass: Evidence-Based Answers to 1000 Questions

Gillian Penney, Susan Brechin and Anna Glasier

Index

[More information](#)

- drug interactions 327–8, 494
- elective surgery 63–4
- in gall bladder disease 447, 448–9, 515–16
- in HIV infection 493–5, 497–8, 499, 500
- in hypermobility syndrome 354
- in ischaemic heart disease 423, 424–7, 430
- in liposarcoma 536
- in liver disease 450–1, 452–5, 457, 458–9, 462
- in migraine 353–6, 357
- in neurofibromatosis 374–5
- in obesity 537–9
- in otosclerosis 376–7
- in polycystic ovary syndrome 542
- postpartum use 59–60, 83–4
- in pulmonary hypertension 410
- in renal disorders 317–19, 463–5, 467–8
- in rheumatoid arthritis 551–2
- risks and sequelae 66–9
- in skin disorders 473, 477, 480, 481–2
- in thrombophilias 438–40, 446, 441–2, 444–5
- in tuberculosis 560–2
- see also* specific types
- progestogen-only emergency
 - contraception 222–33
 - continuing contraception after 13–14, 231–2
 - dose, timing and efficacy 225–8
 - drug interactions 302, 306–8, 328–9, 334, 494
 - in epilepsy 343–4
 - generic vs branded levonorgestrel 260–1
 - more than once in one cycle 229–31
 - patient selection 222–5
 - repeat prescription/advance supply 224–5
 - in trophoblastic disease 564
- progestogen-only implants 116–35
 - adverse effects 129–32
 - after induced abortion 237
 - in anticoagulated patients 411–12, 438–9, 442
 - bone mineral density and 130–1, 198
 - in cerebrovascular disorders 384, 387–3
 - in congenital heart disease 396
 - drug interactions
 - complementary medicines 327–8, 331
 - liver-enzyme inducers 300–1, 303, 305–6, 306–8, 494
 - retinoids 323–4, 324–5
 - tacrolimus 320
 - efficacy 120–4, 125
 - in endometriosis 131–2, 524–5
 - in epilepsy 344, 345, 347, 348–9
 - follow-up 251
 - in HIV infection 493–5, 500
 - insertion and removal 11, 124–9
 - in liver disease 130, 456, 458–9
 - in multiple pathologies 425–7
 - in neurofibromatosis 375
 - in obesity 116–19, 121–2, 539
 - patient selection 116–20, 131–2
 - perimenopause 122–3, 134–5
 - recall systems for removal 257–9
 - in rheumatoid arthritis 551
 - in thrombophilias 438–9, 442, 444–5
 - unscheduled bleeding 132–4
 - in venous thromboembolism 433–4
 - in von Willebrand's disease 564–5
 - see also* etonogestrel-releasing implant; levonorgestrel-releasing implant
- progestogen-only injectables 82–116
 - abnormal bleeding 96–8, 115
 - administration 98–100, 104
 - adverse effects 23, 108–13, 114
 - after induced abortion 237, 238–9
 - anaphylactic and allergic reactions 100–5
 - in anticoagulated patients 442

- bone mineral density and 84–6, 87–8, 90–6, 114–15
- in cerebrovascular disease 384
- dose and regimens 105–7, 116
- drug interactions 299, 301, 332–3, 494
- in endometriosis 524–5
- in epilepsy 344, 347, 349
- in neurofibromatosis 375
- patient selection 82–90
- timing 11
- in venous thromboembolism 433–4
- see also* depot medroxyprogesterone acetate
- progestogen-only pill 57–81
 - after induced abortion 237
 - after oral emergency contraception 14
 - in anticoagulated patients 433–4, 442
 - in benign intracranial hypertension 361–2
 - bone mineral density and 65
 - in breast cancer 485
 - breast cancer risk 65–6, 490–2
 - in cerebrovascular disease 384
 - drug interactions
 - antibiotics 309–10
 - antihistamines 333
 - anti-obesity medications 335–6, 337–8
 - complementary medicines 327–8
 - illegal recreational drugs 341
 - liver-enzyme inducers 303, 305, 309–10, 494
 - retinoids 477
 - warfarin 338
 - efficacy 58, 72–5
 - elective surgery 63–4
 - for emergency contraception 260–1
 - in epilepsy 344, 345
 - family history of breast cancer and 65–6
 - in gall bladder disease 447
 - in heart disease 396, 410–11, 418–19
 - in HIV infection 500
 - in liver disease 462
 - management of adverse effects 69–72
 - missed pills and potential failures 76–9
 - in neurofibromatosis 375
 - in obesity 58–60, 74, 121, 538–9
 - in ovarian cancer 540, 541
 - patient selection 57–63
 - perimenopause 60–2, 81, 279
 - in renal disorders 464–5
 - risks and sequelae 66–9
 - in skin disorders 473
 - starting 11
 - supply arrangements 251
 - in Takayasu arteritis 557–8
 - with topical vaginal estrogens or HRT 79–81
 - travellers to high altitudes 18
 - in tuberculosis 561
- progestogens
 - androgenic 198
 - breast cancer risk 282–3
 - in combined pills 7, 8–9
 - hair loss related to 22
 - vaginal estrogen cream users 282
 - vasomotor symptoms 280–1
- prolactin, serum 363–6, 367
- prolactinomas 363–6, 367
- propylthiouracil 309–11
- prostaglandins
 - cervical priming for IUD insertion 488
 - see also* misoprostol
- prostatic cancer, risk after vasectomy 212–13
- prosthetic heart valves, IUD
 - insertion/removal 157, 190, 407–8
- protein C/protein S deficiency 443
- prothrombin gene mutations 443–4
- proton pump inhibitors 309
- pruritus
 - progestogen-only implant users 130
 - in Schamberg's disease 552
- pseudotumour cerebri *see* benign intracranial hypertension

Cambridge University Press

978-1-904-75233-2 - Family Planning Masterclass: Evidence-Based Answers to 1000 Questions

Gillian Penney, Susan Brechin and Anna Glasier

Index

[More information](#)**590 FAMILY PLANNING MASTERCLASS:** Evidence-based Answers to 1000 Questions

- psoriasis 316–17
- puerperal sepsis, insertion of IUDs after 143
- pulmonary embolism
past history, plus multiple other pathologies 425–7
see also venous thromboembolism
- pulmonary (arterial) hypertension 304–6, 410
- pulmonary stenosis 400–1
- pyrazinamide 561
- pyridoxine (vitamin B6) 287–9, 309–11
- Rathke's pouch cyst 366–7
- Raynaud's phenomenon 509, 548–50
- recall systems, removal of IUDs and implants 257–9
- reception staff 252
- recreational drugs, illegal 339–42
- Reductil® 335–6
- refusal to prescribe 261–3
- renal disorders 463–71
ciclosporin interactions 317–19
Henoch-Schönlein purpura 528
- renal failure 463–4
- renal transplant recipients 464–5
- Replens MD® 34, 80, 282
- resuscitation
in anaphylaxis 100–2, 103
equipment and supplies 249–51
at LNG-IUS removal 187–8
vasovagal syncope, at IUD insertion 162
- retinal vascular lesions 372
- retinoblastoma 377–8
- retinoids 321–5, 477
- rheumatoid arthritis 551–2
- ribavirin 460
- rifabutin 309
- rifampicin
combined oral contraception and 45–6
progestogen-only contraception and 300, 307, 309–10, 561
- Saf-T-Coil 177
- sagittal sinus thrombosis, postnatal 391–2
- saliva ovulation test, Calista® 214–15
- saquinavir 493
- Schamberg's disease 552–3
- Scheuermann kyphosis 553–4
- scleroderma 110
- seizures, frequency of 343–4, 348
- septic abortion, insertion of IUDs after 143
- services, family planning 247–64
design 247–56
legal and ethical issues 257–64
- sexual dysfunction, female 129–30
- sexual intercourse, unprotected
contraception after *see* emergency contraception
pregnancy testing after 265–6
see also back-up contraception/
abstinence from sex
- sexually transmitted infections (STI)
bacterial vaginosis and 188–9
insertion of IUDs after 144, 166, 182
IUD use in HIV infection and 501
in LNG-IUS users 195–6
in nonoxynol-9 users 205–6
screening for *see* microbiology testing
treatment prior to IUD insertion 148–9
- Shanghai ring 217–18
- Shwachman–Diamond syndrome 287
- sibutramine hydrochloride 335–7
- sickle cell disease 554–5
- skin disorders 472–38
in combined pill users 24–6, 472–3, 475, 481
- smokers
combined oral contraception 5
cardiovascular risk factors and 419
inadvertent use during pregnancy 37
for non-contraceptive benefits 30–1
refusal to prescribe 261–3

- sibutramine hydrochloride and 336–7
- Takayasu arteritis and 380, 381
- venous thromboembolism risk 17–18, 30–1
- ventricular septal defects and 401–2
- former, combined oral contraception 5
- progestogen-only injectables 92–4
- on retinoids 324
- solvent abuse, and erectile dysfunction 293
- spatulas, cervical smears 268
- speculums, vaginal
 - cervical smears 267
 - correct plural form 254
 - metal vs plastic 254–6
- spermicides
 - condoms lubricated with 205–6
 - use with diaphragms 206–8
- spider naevi (angiomas) 24–5
- spironolactone, premenstrual syndrome 287–9
- splenectomy, antibiotic prophylaxis for IUD insertion 157–8, 556–7
- Staphylococcus aureus*
 - identified on vaginal swabs 273–4
 - methicillin-resistant (MRSA) *see* methicillin-resistant *Staphylococcus aureus*
 - vaginal discharge in vaginal ring users and 215–16
- starflower oil 331
- steel ring intrauterine devices 217–18
- sterilisation 209–13
 - female *see* female sterilisation
 - male 212–13
- steroid therapy *see* corticosteroid therapy
- Stevens–Johnson syndrome 475
- STI *see* sexually transmitted infections
- St John's wort 325–30
- streptococcus
 - group A 148, 271
 - group B 148, 271
- striae, skin 25
- stroke
 - combined pill-related risks 26
 - hypertension and 19
 - migraine and 350, 351, 352
 - smokers aged over 35 years 30–1
- family history
 - and high cholesterol 392–3
 - and idiopathic thrombocytopenic purpura 531–2
- haemorrhagic 383–4
- hypercholesterolaemia and 392–3, 422, 423–4
- mitral valve prolapse and 399
- past history 383–8, 389–90
 - and valvular heart disease 406
- risk factors 393
 - Takayasu arteritis and 379–81
- subarachnoid haemorrhage 383–4
- supply of contraceptives 251–2
- surgery
 - combined pill users 447–8
 - IUD removal 173, 178–9
 - progestogen-only pill users 63–4
- Sydenham's chorea 378–9
- syncope, vagovagal *see* vasovagal episodes
- systemic lupus erythematosus (SLE) 440–1
 - combined oral contraception 26, 478–9, 548, 549
 - etonogestrel-only implant 448–9
- systemic pulmonary shunts, surgical 407–8
- tacrolimus 319–20, 461, 465, 532–3
- Takayasu arteritis 379–81, 557–8
- tamoxifen 283–5, 484–8
- tear film 27–8
- teenagers *see* adolescents
- teratogenicity *see* fetal abnormalities
- terbinafine 335–6
- termination of pregnancy *see* induced abortion

Cambridge University Press

978-1-904-75233-2 - Family Planning Masterclass: Evidence-Based Answers to 1000 Questions

Gillian Penney, Susan Brechin and Anna Glasier

Index

[More information](#)

- tetralogy of Fallot 395–6, 405–6, 407–8
- thin membrane disease 24
- thrombocytopenic purpura
 - idiopathic 530–2
 - thrombotic 530–1
- thromboembolism, venous *see* venous thromboembolism
- thrombophilias 437–46
 - HRT and 281
 - women with family history of VTE 436–7
- thrombosis, arterial *see* arterial thrombosis
- thyroid disease 309–11, 448–9
- thyroid function tests 198, 279–80
- topiramate 345
- toxic epidermal necrolysis 475
- toxic shock syndrome 215, 216, 273
- training, IUD insertion 155
- tranexamic acid (Cyklokapron®) 193
- transdermal contraception, combined *see* combined transdermal contraception
- transient ischaemic attacks (TIA) 388–9
- transplant recipients 319, 415–16, 461, 464–5
- travel, to extreme altitudes 18
- triazole anti-fungals 315
- Trichomonas vaginalis* 148
- trimethoprim 314
- trophoblastic disease, gestational 558–60
- T Safe® CU 380A IUD 140
- T Safe® CU 380A (FP) IUD 139
- tuberculosis 309–11, 560–2
- ulcerative colitis 562–3
- ultrasound scanning, IUDs 178, 217
- urticaria, progestogen-only injection-associated 102–4
- uterine abnormalities
 - investigation for, after IUD expulsion 157–8
 - LNG-IUS use 184
- uterine fibroids, LNG-IUS use 203–4
- uterine perforation
 - IUD-related 153–4, 155–6, 159–60, 168–9, 173
 - by uterine sound, management 161
- uterine sounding
 - perforation complicating 161
 - protective benefits 153–4
- Vagifem® 80
- vaginal antisepsis 152, 153
- vaginal bleeding, abnormal *see* bleeding patterns, abnormal
- vaginal delivery, IUD insertion after 155–6
- vaginal discharge, vaginal ring users 215–16
- vaginal dryness 34, 79–80, 282
- vaginal estrogens, topical
 - combined pill users 34
 - progestogen-only pill users 79–80
 - progestogens for endometrial protection 282
- vaginal rings
 - contraceptive 215–16
 - estrogen-containing 282
- vaginal swabs *see* microbiology testing
- vaginal ulceration, in nonoxynol-9 users 205–6
- valvular heart disease 395–9, 407–8
 - combined oral contraception 53, 397
 - complicated 397, 410
 - endocarditis prophylaxis *see* endocarditis, prophylaxis
 - IUD insertion/removal 157, 407–8
 - and past history of stroke 406
 - uncomplicated 397
- vasectomy 212–13
- vasomotor symptoms *see* menopausal symptoms
- vasovagal episodes
 - at IUD insertion 162
 - at LNG-IUS removal 188
- Veda-scope 255
- venous thromboembolism (VTE) 433–46

Cambridge University Press

978-1-904-75233-2 - Family Planning Masterclass: Evidence-Based Answers to 1000 Questions

Gillian Penney, Susan Brechin and Anna Glasier

Index

[More information](#)

- Behcet's disease and 509–10
 cocaine use and 340
 combined contraceptive patch users 47–8
 combined pill-related risks 7, 8–9, 436–7
 in cerebral palsy 370–1
 cyproterone acetate-containing pills 9, 49, 50–1, 403
 deep-sea divers 19
 in dermatomyositis 474
 extreme altitudes 18
 gall bladder surgery 448
 lupus anticoagulants 26
 neurosurgical procedures 34–5
 obesity 537
 in Raynaud's phenomenon 548–9
 smokers 17–18, 30–1
 current, treated with anticoagulants 338, 433–5
 family history
 combined oral contraception 436–7
 HRT 281
 liver-enzyme inducers and high BMI 303–4
 Klippel-Trenaunay-Weber syndrome and 445
 past history
 HRT 281
 progestogen-only contraception 435–6–1
 progestogen-only contraception-related risks 435–6, 448
 elective surgery 63–4
 obesity 82
 thrombophilia-related risks 442–3, 443–4
 see also thrombophilias
 ventricular septal defects (VSD), asymptomatic 401–2
 ventriculoperitoneal shunt, in neurofibromatosis 374–5
 vitamin B6 (pyridoxine) 287–9, 309–11
 vitamin C 334
 Vitex agnus castus 330–1
 von Willebrand's disease 563–5
 VTE *see* venous thromboembolism
 vulvar epithelial disorders, non-neoplastic 475–6
 vulvovaginal candidiasis 28–9, 148, 272
 walk-in centres, NHS 247–9
 warfarin
 combined oral contraception and 442–3
 desogestrel-only pill and 338
 endocarditis prophylaxis and 189–90
 etonogestrel implant and 411–12
 intrauterine contraception and 391–2, 433–4, 434–5
 weight, body
 gain
 benign intracranial hypertension and 361
 DMPA users 82, 538
 LNG-IUD users 194–5
 Yasmin users 33–4
 loss, postpartum 36–7
 metformin therapy in PCOS and 291–3
 progestogen-only contraception and 58–60, 74, 116–19, 121
 -related amenorrhoea 20
 see also body mass index; obesity
 Wilson's disease 457
 Wolff-Parkinson-White syndrome 412–13
 Xenical® 337–8
 X-rays, IUD identification 173, 176–7
 Yasmin® *see* drospirenone/
 ethinylestradiol combined pill
 young women
 under 16 years, consent issues 258, 260, 385, 508–9
 cerebrovascular disease 384–5
 cervical screening 252–4